Cynthia Correll, MD
Clinical Neurophysiology · Danville, PANPI 1609036482
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 93 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 16.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,257, 7.2 times the $175 reported in 2023.
Across 93 payments — averaging $22.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$341
- AstraZeneca$175
- SK Life Science, Inc.$163
- UCB, Inc.$150
- Livanova USA, Inc.$137
- Lilly USA, LLC$110
- plus $1K from 23 others
What the payments were for
- Food & beverage$2,06698%
- Other$362%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 15 | $341 |
| AstraZeneca | 7 | $175 |
| SK Life Science, Inc. | 6 | $163 |
| UCB, Inc. | 5 | $150 |
| Livanova USA, Inc. | 7 | $137 |
| Lilly USA, LLC | 6 | $110 |
| Jazz Pharmaceuticals Inc. | 4 | $103 |
| Pfizer | 5 | $92 |
| Catalyst Pharmaceuticals, Inc. | 3 | $77 |
| Merz Pharmaceuticals, LLC | 3 | $69 |
| Lundbeck LLC | 3 | $63 |
| Vanda Pharmaceuticals Inc. | 2 | $54 |
| Biogen | 2 | $49 |
| Teva Pharmaceuticals USA, Inc. | 3 | $47 |
| Eisai Inc. | 2 | $46 |
| ANI Pharmaceuticals, Inc. | 2 | $46 |
| Acadia Pharmaceuticals Inc | 2 | $45 |
| Argenx US, Inc. | 2 | $44 |
| Tanabe Pharma America, Inc. | 2 | $41 |
| Neurelis, Inc. | 2 | $41 |
| Baxter Healthcare | 2 | $36 |
| Amgen | 1 | $33 |
| Alnylam Pharmaceuticals Inc. | 1 | $24 |
| Medtronic | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| TG Therapeutics, Inc. | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Neurocrine Biosciences, Inc. | 1 | $16 |
| Bristol Myers Squibb | 1 | $15 |
How this compares
Too few clinical neurophysiology providers in Pennsylvaniato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpidiolexCannabidiol (Cbd) | 22 | $62,382 |
| Nurtec OdtRimegepant Sulfate | 19 | $41,451 |
| BriviactBrivaracetam | 11 | $27,785 |
| Rufinamide | 13 | $11,832 |
| Lamotrigine ErLamotrigine | 20 | $11,291 |
| Lacosamide | 119 | $10,756 |
| Levetiracetam | 176 | $8,047 |
| Clobazam | 42 | $7,900 |
| Carbamazepine ErCarbamazepine | 27 | $6,493 |
| TegretolCarbamazepine | 11 | $5,419 |
| Oxcarbazepine | 38 | $3,658 |
| Divalproex Sodium ErDivalproex Sodium | 38 | $3,586 |
| Carbamazepine | 34 | $2,873 |
| Lamotrigine | 125 | $2,521 |
| Tegretol XrCarbamazepine | 12 | $2,361 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $92 | $41,45119 claims |
| UCB, Inc.Briviact | $150 | $27,78511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical neurophysiology providers in Pennsylvaniaon file to place this against a meaningful peer group, so we don't.
Other clinical neurophysiology in Danville
- Saira SaadHarrisburg$48K
- Zachary SimmonsHershey$43K
- Sandeep RanaPittsburgh$30K
- Venkatraman ThulasiBethlehem$29K
- Sonya KnightBlue Bell$19K
- Venkata JakkampudiHershey$7K
- Charles BaePhiladelphia$7K
- Jagdish ShahMechanicsburg$3K
- Laxmi ShahMonroeville$2K
- Karen CarvalhoPhiladelphia$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.